HORSHAM, PA, USA-DECEMBER 28, 2010-DIA today announced the launch of its Regulatory Affairs Certificate Program. The Regulatory Affairs Certificate Program is the fourth certificate program developed by DIA.
DIA's Regulatory Affairs Certificate Program provides comprehensive training on current regulations and their practical application to the development and commercialization of pharmaceutical, biotechnology, medical device, and related health care products. The curriculum features courses in:
US Regulatory Affairs: IND and NDA/CTD Phases
EU Regulatory Requirements
Preparing for FDA Meetings
Post-approval Regulatory Requirements
Regulatory Requirements for Product Labeling and Advertising
Regulation of Drug, Medical Device, and Biologic Products
Quality Assurance
Other DIA Certificate Programs include:
Project Management
Clinical Research
Clinical Safety and Pharmacovigilance
"Our world-class faculty addresses the practical and theoretical aspects of the conduct of pharmacovigilance, with emphasis on understanding of the concepts, themes underlying effective processes, and the basic tenets of global regulatory compliance with safety principles," says Katie Hill, DIA Senior Training Manager.

Enroll in DIA's Regulatory Affairs Certificate Program.

DIA is a neutral, global, professional, member-driven association of nearly 18,000 professionals involved in the discovery, development, and life cycle management of pharmaceuticals, biotechnology, medical devices, and related health care products. Through our international educational offerings and myriad networking opportunities, DIA provides a global forum for knowledge exchange that fosters the innovation of products, technologies, and services to improve health and well being worldwide. Headquarters are in Horsham, PA, USA, with offices in Basel, Switzerland, Tokyo, Japan, Mumbai, India, and Beijing, China.

Suggested Articles

Maryland-based Emergent BioSolutions has won a $628 million contract with BARDA to manufacture targeted COVID-19 vaccine hopefuls.

About 76% remdesivir patients had at least one point of clinical improvement on a 7-point scale at day 11, versus 66% of patients on standard care.

Alexion and Amgen reached a deal to put off a biosimilar challenger to Alexion's blockbuster rare disease med Soliris until March 2025.